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ABSTRACT
Objective To evaluate the relative effectiveness of
hysterectomy, endometrial destruction (both “first
generation” hysteroscopic and “second generation” non-
hysteroscopic techniques), and the levonorgestrel
releasing intrauterine system (Mirena) in the treatment of
heavy menstrual bleeding.
DesignMeta-analysis of data from individual patients,
with direct and indirect comparisonsmade on the primary
outcome measure of patients’ dissatisfaction.
Data sources Data were sought from the 30 randomised
controlled trials identified after a comprehensive search
of the Cochrane Library, Medline, Embase, and CINAHL
databases, reference lists, and contact with experts. Raw
data were available from 2814 women randomised into
17 trials (seven trials including 1359 women for first v
second generation endometrial destruction; six trials
including 1042 women for hysterectomy v first generation
endometrial destruction; one trial including 236 women
for hysterectomy v Mirena; three trials including 177
women for second generation endometrial destruction v
Mirena).
Eligibility criteria for selecting studies Randomised
controlled trials comparing hysterectomy, first and
second generation endometrial destruction, and Mirena
for women with heavy menstrual bleeding unresponsive
to other medical treatment.
Results At around 12 months, more women were
dissatisfied with outcome with first generation
hysteroscopic techniques than with hysterectomy (13% v
5%; odds ratio 2.46, 95% confidence interval 1.54 to 3.9,
P<0.001), but hospital stay (weighted mean difference 3.
0 days, 2.9 to 3.1 days, P<0.001) and time to resumption
of normal activities (5.2 days, 4.7 to 5.7 days, P<0.001)
were longer for hysterectomy. Unsatisfactory outcomes
were comparable with first and second generation
techniques (odds ratio 1.2, 0.9 to 1.6, P=0.2), although
second generation techniques were quicker (weighted
mean difference 14.5 minutes, 13.7 to 15.3 minutes,
P<0.001) and women recovered sooner (0.48 days, 0.20
to 0.75 days, P<0.001), with fewer procedural
complications. Indirect comparison suggested more
unsatisfactory outcomes with second generation
techniques thanwith hysterectomy (11% v 5%; odds ratio
2.3, 1.3 to 4.2, P=0.006). Similar estimates were seen
when Mirena was indirectly compared with hysterectomy
(17% v 5%; odds ratio 2.2, 0.9 to 5.3, P=0.07), although
this comparison lacked power because of the limited
amount of data available for analysis.
ConclusionsMore women are dissatisfied after
endometrial destruction than after hysterectomy.
Dissatisfaction rates are low after all treatments, and
hysterectomy is associated with increased length of stay
in hospital and a longer recovery period. Definitive
evidence on effectiveness of Mirena compared with more
invasive procedures is lacking.
INTRODUCTION
Heavy menstrual bleeding is a common problem in
women of reproductive age.1 It is often incapacitating
and expensive to treat and can severely affect a
woman’s quality of life.2 3 Many women are not
happy with medical treatment and end up undergoing
surgery.4 Hysterectomy was once the only surgical
option for heavy menstrual bleeding, and almost half
of the hysterectomies currently performed worldwide
are carried out for this reason.5 Endometrial destruc-
tion techniques, which aim to destroy or remove the
endometrial tissue,6 have become increasingly popular
alternatives, and, as a result, the number of hysterec-
tomies in the United Kingdom declined by 64%
between 1995 and 2002.7 They were introduced in
the 1980s, with rollerball ablation and transcervical
resection emerging as the main approaches under
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direct hysteroscopic vision.8 Subsequently, second
generation non-hysteroscopic techniques have been
developed, which are easier to perform. Here, devices
are sited and activated to treat the whole endometrial
cavity simultaneously without visual control. Destruc-
tion is achieved through various methods, including
high temperature fluids and bipolar electrical ormicro-
wave energy. Intrauterine devices were initially intro-
duced as contraceptives, but the addition of
progestogen resulted in reduced menstrual bleeding.
Mirena, the levonorgestrel releasing intrauterine sys-
tem, provides a non-surgical alternative, which is
reversible and spares fertility.9
Women and clinicians now have a greater choice of
treatment, although evidence to support decisionmak-
ing is inadequate. In the UK, guidelines from the
National Institute for Health and Clinical
Excellence10 recommend the use of Mirena in the
first instance for women with benign heavy menstrual
bleeding, followed by endometrial destruction, if drug
treatments fail to resolve symptoms. Syntheses of evi-
dence from randomised controlled trials comparing
these treatments have been limited,11-13 partly because
of scarcity of head to head comparisons and variation
in outcome measurements used to evaluate effective-
ness. We undertook a meta-analysis of data from indi-
vidual patients from all relevant trials to address
previous deficiencies in evidence synthesis. This sort
of meta-analysis has several advantages over tradi-
tional reviews of published data,14 including the ability
to carry out data checks, standardise analytical meth-
ods, and undertake subgroup analyses.
METHODS
We sought data on individual patients from rando-
mised controlled trials of hysterectomy, endometrial
destruction techniques, and Mirena to examine their
relative efficacy as second line treatment for heavy
menstrual bleeding. The systematic review was con-
ducted based on a protocol designed with widely
recommended methods15 16 that complied with guide-
lines for reporting meta-analysis17 (www.bctu.bham.
ac.uk/systematicreview/hmb/protocol.shtml).
Literature search and study selection
We searched the Cochrane Library, Medline (1966-
2010), Embase (1980 to May 2010), and CINAHL
databases (1982 to May 2010) using relevant terms
and word variants for population and interventions
(see appendix 1 on bmj.com). We also hand searched
the bibliographies of all relevant primary articles and
reviews to identify any articlesmissed by the electronic
searches. Experts were contacted to identify further
studies. To identify any ongoing randomised
Satisfaction
as an outcome
within 2 years
(with IPD)
Articles retrieved for detailed evaluation (n=111)
Total citations identified (n=557)
Articles included (n=39)
Articles included in systematic review and meta-analysis (n=40) 
Unpublished studies (n=1*)
Articles excluded (n=72):
  Abstract/letter (n=6)
  Data not extractable (n=9) 
  Duplicates (n=57)
Trials unable to contribute to meta-analysis (n=10): 
  First generation v first generation (n=4)
  Second generation v second generation (n=4) 
  Hysterectomy v hysterectomy (n=2)
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endometrial destruction
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endometrial destruction
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Hysterectomy
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Fig 1 | Study selection process for systematic review and meta-analysis of data from individual patients from randomised trials
comparing hysterectomy, endometrial destruction techniques, and Mirena for heavy menstrual bleeding (see appendix 2 on
bmj.com for details of selected trials). IPD=individual patient data. *Study was comparison of second generation endometrial
destruction techniques and did not contribute to meta-analysis
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controlled trials, we searched the Meta-Register of
Controlled Trials and the ISRCTN register. No lan-
guage restriction was applied.
Studies were selected in a two step process. Firstly,
we scrutinised the citations identified by the electronic
searches and obtained full manuscripts of all the cita-
tions that met, or were thought likely to meet, the pre-
determined inclusion criteria based on patients’ entry
criteria (women with heavy menstrual bleeding or
abnormal/excessive/prolonged uterine bleeding that
was unresponsive to other medical treatment) and
study design, the latter limited to randomised con-
trolled trials. We then considered four categories of
intervention: hysterectomy (performed abdominally,
vaginally, or laparoscopically); “first generation”
endometrial destruction techniques (using operative
hysteroscopy, including endometrial laser ablation,
transcervical resection of the endometrium (TCRE),
and rollerball endometrial ablation); “second genera-
tion” endometrial destruction techniques (those that
use a “blind” device to simultaneously treat the whole
cavity, including thermal balloon (Cavaterm, Therma-
choice, and Vesta), microwave (Microsulis), laser
(ELITT), bipolar radio frequency (NovaSure), cryo-
ablation, and hydrothermal ablation); and a levonor-
gestrel releasing intrauterine system (Mirena). We
compared these categories of treatment against each
other; studies were excluded from the meta-analysis if
a comparison between relevant categories did not
exist, although we also requested data from studies
making a comparison within these categories to allow
further exploration of possible predictors of the pri-
mary outcome measure.
Data collection and study quality assessment
We made repeated attempts to contact corresponding
authors via post, email, or telephone to access data.
When initial attempts failed, we attempted personal
contact via our links through the British and European
Societies for Gynaecological Endoscopy. Authors
were asked to supply anonymised data for each of the
prespecified outcome measures and were invited to
become part of the collaborative group with joint own-
ership of the final publication. When investigators
declined to take part in the study or could not be con-
tacted, two independent reviewers (RC and LJM)
extracted published data from manuscripts using pre-
designed proformas. Any disagreements were
resolved by consensus or arbitration by a third
reviewer (JPD).Receiveddataweremerged into amas-
ter database, specifically constructed for the review.
The data were cleaned and results cross checked
against published reports of the trials.Whendiscrepan-
cies existed we contacted authors for clarification.
Authors of the protocol reviewed all relevant out-
come measures to be used in the meta-analysis from
articles identified in the literature search. Level of satis-
faction with treatment was the most commonly mea-
sured outcome across all identified studies, with 21 out
of 30 (70%) using this measure, and we used it as our
primary outcome measure. Dissatisfaction rates are
presented to simplify interpretation of statistical
Compliance (%)
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endometrial destruction Hysterectomy v Mirena
1st v 2nd generation
endometrial destruction
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Follow-up >80%
Compliance with allocated treatment
  >80% in both arms at 12 months
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endometrial destruction
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endometrial destruction Summary of all studies
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Fig 2 | Quality of studies included in systematic review and meta-analysis of individual patient data from randomised trials
comparing hysterectomy, endometrial destruction techniques, and Mirena for heavy menstrual bleeding. Numbers inside bars
are numbers of studies (details given in appendix 3 on bmj.com)
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output. Responses of “very satisfied” or “satisfied”
were taken as a positive response, likewise “very dissa-
tisfied” or “dissatisfied” were taken as a negative
response. Where a “not sure” or “uncertain” response
was given thesewere conservatively taken to be a nega-
tive rating of treatment, although we carried out a sen-
sitivity analysis to test the robustness of this
assumption. For a small number of studies,18-21 we
used surrogate outcomes for satisfaction (major pro-
blem resolved/improvement of health state/menstrual
symptoms successfully treated/degree of recommen-
dation). This assumption was also tested by sensitivity
analysis without these studies (indicated in the results
sectionwhere important) (see appendix2onbmj.com).
Amore disease specific quality of life tool22 would have
been the ideal choice for primary measure, but rele-
vant datawere not available from the identified studies.
We have shown from the data in this review, though,
that there is a strong relation between dissatisfaction
and patients’ quality of life (see results section).
Other outcomemeasures were bleeding scores (ran-
ging from a minimum of zero with no upper limit),23
amenorrhoea rate (converted from a bleeding score
of zero where data existed, otherwise as reported),
heavy bleeding rate (converted frombleeding scores of
>10023 where data existed, otherwise as reported), EQ-
5D utility score,24 SF-36 scores,25 duration of surgery/
hospital stay, rates of general anaesthesia, postopera-
tive pain score (standardised from visual analogue
and ordinal scale scores on to a scale of 0-10), time to
return to work/normal activities/sexual activity, dys-
menorrhoea/dyspareunia rate, and proportion under-
going subsequent ablation/hysterectomy or
discontinuing use of Mirena. Predefined subgroups
were age at randomisation (≤40 v>40), parity (nullipar-
ous v parous), length of uterine cavity (≤8 v >8 cm),
presence or absence of fibroids/polyps, and, when
available, severity of bleeding at baseline (bleeding
score ≤350 or >350).
We assessed all selected trials for their methodologi-
cal quality by using received datasets when available in
addition to the reported information.Qualitywas scru-
tinised by checking adequacy of randomisation, group
comparability at baseline (examining baseline charac-
teristics for any substantive differences), blinding
(where appropriate), use of intention to treat analysis,
completeness of follow-up, compliance, reliability by
using a priori estimation of sample size, and generali-
sability by using a description of the sample recruited.
Adequacy of randomisation was assessed with sub-
questions examining information on sequence genera-
tion, the process of allocation, and allocation conceal-
ment.
Statistical analysis
To minimise the possibility of bias, we combined data
on individual patients and aggregate data in a two stage
approach.26 Data on individual patients were reduced
to aggregate data to allow studies with only aggregate
data to be combinedwith those with data on individual
patients. Unless specifically stated, all estimates shown
are from all available data (both individual patient data
and aggregate data). Point estimates and 95% confi-
dence intervals were calculated for individual studies
at each time point. Differences in effect estimates
between trials and the predefined subgroups of
patients are displayed with odds ratio plots, with het-
erogeneity investigated by using Cochran’s Q27 and I2
statistics.28 Subgroup analyses to explore the causes of
heterogeneity were undertaken if the P values of these
tests were <0.1. Differences between studies contribut-
ing data on individual patients and those with only
aggregate data were examined in the same fashion to
check that the latter results were consistent with those
for which we received individual data. Limited data
were available for studies comparing Mirena with
endometrial destruction, so we compared Mirena
with first and second generation studies combined as
well as separately. We used assumption-free “fixed
effect” methods to combine dichotomous outcome
measures and estimate pooled odds ratios using the
method of Peto,29 and, for continuous variables, calcu-
lated weighted mean differences30 at each time point.
Data at less than 12 months were combined and are
described as results at six months. Results from the
limited number of studies with follow-up longer than
two years are not referred to in the text but are given in
the appendices (see bmj.com).
The primary outcomemeasure of dissatisfactionwas
investigated comprehensively by using received data.
Results at 12 months, when most studies had collected
data, were used as the focus for analysis. When
responses were not available at this time point, data
were substituted, in the first instance, from two years
and failing that six months. Estimates of dissatisfaction
at any time were also examined, along with an analysis
allowing for the correlation of the repeated measure-
ments using generalised estimating equations (data on
individuals patient only).31 If we could not directly
compare treatments, we made indirect estimates32
using a logistic regression model33 allowing for trial
and treatment.34 For example, we estimated the effect
for the comparisonof hysterectomyversus secondgen-
eration endometrial destruction using the common
comparators of first generation endometrial destruc-
tion and Mirena. It should be noted that for this
  Dickersin37
  Crosignani31
  O'Connor34
  Pinion35
  Dwyer32
Total (95% CI)
Heterogeneity: χ2=1.15, df=4, P=0.89; I2=0%
Test for overall effect: z=3.75, P<0.001
1.86 (0.55 to 6.21)
2.61 (0.34 to 19.85)
1.61 (0.24 to 10.65)
2.81 (0.76 to 10.39)
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2.46 (1.54 to 3.93)
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Fig 3 | Dissatisfaction at 12 months: hysterectomy v first generation endometrial destruction
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particular analysis we assumed that there are no sys-
tematic differences between the sets of trials that
could bias the indirect measure.32
Access to data from individual patients also allowed
the inclusionof patient level covariates to examinepos-
sible predictors of dissatisfaction. Firstly, we consid-
ered covariates individually, while allowing for
differences between trial estimates by including this
parameter in the model. If considered statistically
important (P<0.1), we included covariate parameters
together in a multivariable analysis to examine
adjusted estimates. In addition to the analysis of the
primary outcomemeasure described above, as a sensi-
tivity analysis, we also used data from individual
patients to explore the effect observed in compliance
rates for comparisons between first and second genera-
tion endometrial destruction (unfortunately therewere
insufficient data to extend this analysis to comparisons
withMirena). For example, for thosewomenwhowere
“satisfied”with treatment but subsequently underwent
a hysterectomy, positive responses were substituted
with negative ones. The relation between dissatisfac-
tion and responses from the SF-36 quality of life ques-
tionnaire was examined at the patient level by using a
regression model allowing for trial. We used Revman
v5.0 (Cochrane Collaboration, Denmark) and SAS
v9.2 (SAS Institute, Cary, USA) software for analyses.
RESULTS
Trials and patients
We identified 556 potentially relevant citations by
electronic searches. After detailed evaluation, 30 trials
were eligible for inclusion in the review (fig 1).Of these
trials, seven compared hysterectomywith endometrial
destruction techniques. Six of these studies involved
first generation techniques. 18 35-39 The seventh study
used a combination of first and second generation in
equal proportions40 and was included here as a first
generation comparison, with a sensitivity analysis per-
formed without the trial. One study compared hyster-
ectomywithMirena. 41 Fourteen studies compared first
generation endometrial destruction techniques with
second generation techniques, 19 42-54 and eight studies
compared Mirena with endometrial destruction, three
of which were first generation2055 56 and five second
generation. 21 57-60 Appendix 2 on bmj.com shows the
characteristics of these studies. Data from a further
five studies (including one unpublished study), 61-64
which involved comparisons within first and second
generation endometrial destruction, were also
received.
Trials that compared hysterectomy with endo-
metrial destruction and those that compared first and
second generation endometrial destruction involved
women of a similar age, with average ages of 40.6
Table 1 | Results from regression analysis comparing satisfaction response with results from SF-36 quality of life
questionnaire at 12 months
SF-36
domain
Change from baseline Absolute
No of
women Mean (SD)
Difference* (95%
CI) P value
No of
women Mean (SD) Difference* (95% CI) P value
General health:
Dissatisfied 71 −4.7 (14.2)
7.4 (3.1 to 11.8) <0.001
91 60.3 (20.5)
12.5 (8.5 to 16.6) <0.001
Satisfied 507 5.7 (17.0) 642 77.7 (17.8)
Physical function:
Dissatisfied 70 0.4 (19.4)
2.8 (−2.6 to 8.3) 0.3
89 78.1 (27.2)
10.9 (6.7 to 15.1) <0.001
Satisfied 497 6.0 (20.7) 637 91.0 (16.6)
Role physical:
Dissatisfied 71 5.3 (51.6)
17.4 (5.3 to 29.4) 0.005
90 60.8 (45.1)
24.0 (17.0 to 31.0) <0.001
Satisfied 504 25.2 (44) 641 88.4 (27.9)
Role emotional:
Dissatisfied 71 4.2 (54.6)
15.0 (2.9 to 27.0) 0.02
90 61.1 (44.2)
23.4 (16.3 to 30.4) <0.001
Satisfied 505 18.2 (44.4) 641 87.4 (28.2)
Mental health:
Dissatisfied 71 −2.1 (22.7)
10.5 (5.4 to 15.6) <0.001
90 58.5 (21.6)
16.9 (12.8 to 21.0) <0.001
Satisfied 504 7.6 (18.7) 638 76.9 (17.1)
Social function:
Dissatisfied 70 4.9 (26.2)
6.7 (0.9 to 12.5) 0.02
90 61.0 (24.2)
17.6 (13.5 to 21.7) <0.001
Satisfied 471 11.6 (21.2) 629 85.5 (18.6)
Vitality:
Dissatisfied 70 6.5 (23.7)
8.5 (2.4 to 14.6) 0.006
91 43.6 (23.1)
18.9 (14.1 to 23.8) <0.001
Satisfied 503 15.7 (22.9) 637 65.2 (21.0)
Pain:
Dissatisfied 71 6.4 (34.3)
9.1 (0.8 to 17.4) 0.03
91 57.6 (27.2)
20.2 (14.7 to 25.6) <0.001
Satisfied 504 20.1 (31.4) 642 81.0 (23.4)
*Adjusted for study.
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(SD 5.1) and 41.0 (SD 4.9), respectively. Women in
trials comparing Mirena with endometrial destruction
were slightly older, with an average age of 43.6 (SD
3.5). Eligibility criteria for women with uterine pathol-
ogy varied between trials; inclusion of women with
fibroids was generally limited by size or number of
the fibroids. When affected women were included,
they amounted to a maximum of 30% of the women
in each individual study.
We received a high proportion of data from trials
involving hysterectomy (7/8 studies, 1278/1363
women) and less from trials of endometrial destruction
techniques (7/14 studies, 1359/2448 women) and
those that comparedMirenawith endometrial destruc-
tion (3/8 studies, 177/494 women) (see appendix 2 on
bmj.com). Overall, we received some data on indivi-
dual patients from 65% (2814/4305) of women
involved in the trials, although only eight studies
were able to provide all requested
variables.36 37 42 43 46 49 54 60 The remaining studies had
some missing information, with limited details on fol-
low-up of patients covering subsequent operations (for
example, hysterectomy after Mirena). Details on how
we used data from studies providing data from indivi-
dual patients are in the section on statistical analysis.
Study quality
Themethodological quality of the studies was variable
(fig 2 and appendix 3 on bmj.com). More than half the
studies failed to give adequate information about their
randomisation procedure and details of allocation con-
cealment. There was a general lack of true intention to
treat analysis, with some studies stating that an inten-
tion to treat had been performed yet analysing only
those women who had received treatment. For four
studies that reported per protocol analyses, 43 46 49 58
intention to treat analyses were undertaken with the
available data on individual patients, although it was
not always clear if patients who deviated fromprotocol
were followedup correctly in these cases. Small sample
sizes often lacked a sensible justification, especially in
studies involving Mirena. In the nine trials involving
Mirena, only four had more than 80% of women with
Mirena in situ 12 months after randomisation.
Dissatisfaction as an outcome measure
Data from four studies that provided data from indivi-
dual patients on both outcomes36 49 51 58 showed that
satisfied patients had significantly increased scores in
seven of eight domains of the SF-36 quality of life ques-
tionnaire when compared with dissatisfied patients in
the analysis of change from baseline scores, including
the general health perception (7.4 points, 95% confi-
dence interval 3.1 to 11.8, P<0.001) and mental health
(10.5 points, 5.4 to 15.6, P<0.001) domains (table 1).
Differences from absolute values (not adjusted for
baseline score) were highly significant (P<0.001) in
all eight domains in favour of satisfied patients.
Effectiveness in reducing dissatisfaction with treatment
Hysterectomy v first generation endometrial destruction—
More women were dissatisfied at 12 months after first
generation endometrial destruction than after hyster-
ectomy (13% (57/454) v 5% (23/432); odds ratio 2.5,
1.5 to 3.9, P<0.001) (fig 3), with no significant hetero-
geneity between study estimates (P=0.9, I2=0%). This
estimate of effect size was consistent with, although
slightly less than, the estimate from the repeated mea-
sures analysis (individual patient data only) over all
time points (3.8, 2.2 to 6.5, P<0.001) and an analysis
using dissatisfaction at any time point (3.4, 2.1 to 5.3,
P<0.001). There was no evidence of any differences
between subgroups (see data collection and study qual-
ity assessment section), including between studies pro-
viding individual patient data or aggregate data (test for
heterogeneity P=0.9).
First v second generation endometrial destruction techni-
ques—Similar rates of dissatisfaction were seen with
first and second generation endometrial destruction
(12% (123/1006) v 11% (110/1034); odds ratio 1.2,
0.9 to 1.6, P=0.2; test for heterogeneity P=0.7, I2=0%)
(fig 4). Comparable estimates were obtained from the
repeated measures analysis of data from individual
patients (1.2, 0.8 to 1.7, P=0.3), the analysis of dissatis-
faction at any time (1.2, 0.9 to 1.6, P=0.2), and an ana-
lysis adjusted for patients who went on to receive
hysterectomy (1.3, 0.9 to 1.7, P=0.1). Results were con-
sistent over all subgroups, including those studies pro-
viding data from individual patient or only aggregate
data (test for heterogeneity P=0.8).
Mirena v endometrial destruction techniques—Rates of
dissatisfaction with Mirena and second generation
endometrial destruction were similar (18% (17/94) v
23% (23/102); odds ratio 0.8, 0.4 to 1.5, P=0.4) (fig 5).
The combined estimate of this and the one study that
compared Mirena with first generation endometrial
destruction20 (test for differences between subgroups
P=0.2) also showed no evidence of a difference (0.9,
0.5 to 1.8, P=0.9; test for heterogeneity over all studies
P=0.1, I2=54%). Overall rates of dissatisfaction were
17% (22/128) for Mirena and 18% (25/137) for both
first and second generation endometrial destruction.
Lack of data from individual patients prohibited any
further investigation of subgroups or repeated mea-
sures. Sensitivity analysis performed without two stu-
dies that used surrogates for dissatisfaction
Table 2 | Results from logistic regression analysis with dissatisfaction at 12 months as
outcome. Figures are odds ratios* (95% confidence intervals)
Individual estimates† Hysterectomy
1st generation
endometrial destruction
2nd generation
endometrial destruction
Uterine cavity length (≤8 v
>8 cm)
— 0.97 (0.38 to 2.4), P=0.9 0.59 (0.38 to0.93), P=0.02
Age (≤40 v >40 years) 2.3 (0.66 to 7.9), P=0.2 1.2 (0.81 to 1.8), P=0.4 1.3 (0.87 to 1.9), P=0.2
Fibroids/polyps (absence v
presence)
0.51 (0.14 to 1.9), P=0.3 1.2 (0.55 to 2.4), P=0.7 0.36 (0.12 to 1.1), P=0.07
Parity(nullparousvparous) — 1.3 (0.36 to 4.4), P=0.7 0.84 (0.33 to 2.2), P=0.7
Baseline bleeding score
(≤350 v 350)
— 0.73 (0.27 to 1.97), P=0.5 0.96 (0.48 to 1.9), P=0.9
*Odds ratio <1 favours first subgroup listed—that is, women have reduced dissatisfaction.
†After adjustment for study.
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significantly reduced the data available for analysis but
did not change the findings.
Indirect comparisons of hysterectomy with second genera-
tion endometrial destruction techniques and Mirena—Indir-
ect estimates (fig 6) suggest that hysterectomy is also
preferable to second generation endometrial destruc-
tion (5% (23/432) v 11% (110/1034); odds ratio 2.3, 1.3
to 4.2, P=0.006) in terms of patients’ dissatisfaction.
This was confirmed by the repeated measures analysis
(individual patient data only) over all three time points
(3.1, 1.6 to 5.9, P<0.001). The evidence to suggest hys-
terectomy is preferable toMirenawas weaker (5% (23/
432) v 17% (22/128); 2.2, 0.9 to 5.3, P=0.07), but given
the lack of precision fromMirena comparisons thiswas
not a surprising result and should be interpreted cau-
tiously.
Predictors of dissatisfaction—For second generation
endometrial destruction, data from individual patients
showed that the length of the uterine cavity was the
strongest predictor of dissatisfaction (P=0.02), with
shorter cavities (≤8 cm v >8 cm) being associated with
reduced rates (odds ratio 0.6, 0.4 to 0.9; P=0.02)
(table 2). Absence of fibroids/polyps also showed a
trend towards reduced dissatisfaction (P=0.07),
although no further adjusted estimates including both
parameters were attempted as only three studies had
data on fibroids/polyps. There were no convincing
associations with any of the variables for hysterectomy
or first generation endometrial destruction.
Effectiveness in improving other outcomes
Hysterectomy v endometrial destruction and Mirena—These
comparisons focused on recovery times and quality of
life because estimates of postoperative menstrual
blood loss are redundant after hysterectomy (see
appendix 2 on bmj.com). Endometrial destruction
offered quicker surgery (weighted mean difference
32 minutes, 30 to 34 minutes, P<0.001), shorter hospi-
tal stay (3.0 days, 2.9 to 3.1 days, P<0.001), faster
recovery periods (time to return to normal activities 5.
2 days, 4.7 to 5.7 days, P<0.001), and less postopera-
tive pain (2.5 points, 2.2 to 2.9 points, P<0.001),
although estimates of differences for some of these
results should be used with caution given the high
variability between studies (see appendix 4 on
bmj.com). One study suggested no obvious difference
in EQ-5D utility score,40 while another suggested dif-
ferences in favour of hysterectomy in the general
health (9.6 points, 5.7 to 13.5 points, P<0.001), social
functioning (24 points, 21 to 27 points, P<0.001), and
vitality (13 points, 9.3 to 16 points, P<0.001) domains
of the SF-36 questionnaire (change from baseline).18
Relatively few perioperative adverse events were asso-
ciated with hysterectomy (0.5%-2% each), but urinary
tract infections were more common (8%, 43/530) than
with endometrial destruction (2%, 9/585) (odds ratio
4.4, 2.5 to 7.8, P<0.001). Of the womenwhowere initi-
ally treated with endometrial destruction, 15% (38/
246) had undergone a hysterectomy by two years.
There were no differences in EQ-5D scores at six or
12months in the single study comparing hysterectomy
with Mirena (see appendix 5 on bmj.com), while the
only significant effect observed in the SF-36 question-
naire was in the pain domain (change from baseline),
favouring hysterectomy (weightedmean difference 9.6
points, 2.7 to 16.6 points, P=0.007). All results were
consistent over subgroups.
First v second generation endometrial destruction techni-
ques—The proportion of women with amenorrhoea
or still experiencing heavy bleeding was similar in
both groups at all time points, apart from at two
years, where there was a difference of borderline sig-
nificance in favour of second generation techniques
(odds ratio 0.64, 0.41 to 0.99, P=0.04, for amenorrhea;
0.54, 0.30 to 0.97, P=0.04, for heavy bleeding) (see
appendix 6 on bmj.com). Change from baseline analy-
sis of bleeding scores showed no evidence of a differ-
ence at any of the time points. Two studies49 51 using the
SF-36 questionnaire and one small study42 using the
EQ-5D questionnaire showed no consistent difference
between first and second generation techniques in
terms of change from baseline results. Second genera-
tion endometrial destruction was quicker (weighted
mean difference 14.5 minutes, 13.7 to 15.3 minutes,
P<0.001) and less likely to require general anaesthesia
(odds ratio 0.16, 0.12 to 0.20, P<0.001), although
highly significant heterogeneity makes estimates diffi-
cult to interpret. Lower use of general anaesthesia with
second generation endometrial destruction translated
to a slightly quicker time to normal activities (weighted
mean difference 0.48 days, 0.20 to 0.75 days, P<0.001)
and time to return towork (1.36 days, 0.69 to 2.03 days,
P<0.001). Postoperative pain was similar after either
method. Adverse events were relatively low in both
groups (<2% each), but perioperative complications
such as uterine perforation (odds ratio 0.20, 0.07 to
0.57, P=0.003), excessive bleeding (0.14, 0.03 to 0.55,
P=0.005), fluid overload (0.12, 0.04 to 0.36, P<0.001),
and cervical laceration (0.12, 0.05 to 0.33, P<0.001)
were lower with second generation techniques. The
Events/total
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  Duleba44
  Hawe39
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  Cooper45
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  Soysal41
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Fig 4 | Dissatisfaction at 12 months: first v second generation endometrial destruction
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number of women requiring a subsequent hysterect-
omy was lower for second generation endometrial
destruction, but these differences were not large
enough to be significant within the first two years
(odds ratio 0.77, 0.47 to 1.24, P=0.3, at 12 months;
0.68, 0.41 to 1.13, P=0.1, at two years). Overall rates
were 3% (74/2265) and 8% (71/939) at these time
points. Any differences among subgroups were con-
fined to single time points only. Results from studies
providing data from individual patients were consis-
tent with those with only aggregate data.
Mirena v endometrial destruction techniques—More
women experienced heavy bleeding after endometrial
destruction at six months (odds ratio 4.3, 1.8 to 10.6,
P=0.001) and at two years (13.0, 2.0 to 84.2, P=0.007),
although not at 12 months (1.4, 0.6 to 2.97, P=0.5),
when the largest number of women was evaluated
(see appendices 7 and 8 on bmj.com). Rates of amenor-
rhoea were similar at all time points. Change in bleed-
ing scores favoured endometrial destruction only at
12 months (weighted mean difference 38 points, 15 to
60 points, P<0.001). Other outcome measures could
not separate the two treatments. Two studies provided
SF-36 change from baseline scores, and no differences
were found in any of the domains.58 60 The number of
women subsequently undergoing a hysterectomy was
similar at each time point; rates at 12 months were 2%
(2/86) for endometrial destruction and 7% (6/89) for
Mirena (odds ratio 0.36, 0.09 to 1.48, P=0.2). A high
proportionofwomenoriginally prescribedMirenadis-
continued use of this treatment: 16% (30/191) at
12 months rising to 28% (29/105) by two years.
Reported adverse events were low with Mirena; only
around 3% reported an expelled or migrated coil
within the first month. These results were from studies
of first and second generation studies combined, when
first generation data existed, and were consistent over
both types of endometrial destruction.
DISCUSSION
Main findings
In women undergoing second line treatment for heavy
menstrual bleeding, both first and second generation
endometrial destruction techniques were associated
with greater dissatisfaction than hysterectomy,
although rates were low for all treatments and absolute
differences were small. Recovery times and length of
hospital staywere longer for hysterectomy.Dissatisfac-
tion levels with second generation techniques were
slightly lower than those associated with first genera-
tion techniques. In addition, second generation meth-
ods were quicker, associated with faster recovery
times, and associated with fewer adverse procedural
events and could be carried out under local anaesthe-
sia. Fewer women subsequently underwent hysterect-
omy after second generation compared with first
generation endometrial destruction, but this difference
was not significant. Shorter uterine cavity length was
associated with lower levels of dissatisfaction for sec-
ond generation endometrial destruction. Comparisons
of endometrial destruction with a levonorgestrel
releasing intrauterine system (Mirena) suggest com-
parable efficacy, although studies of Mirena were gen-
erally small and consequently imprecise. Substantial
discontinuation of use of Mirena was noted and
makes interpretation of findings for this treatment dif-
ficult. The primary outcomemeasure of dissatisfaction
with treatment was shown to be strongly related to
reduced quality of life.
Strengths and limitations
Access to data from individual patients enabled amore
rigorous analysis than is possible from published data.
We used optimal methods, complying with guidelines
on reporting of systematic reviews and meta-
analyses.65 An extensive literature search was con-
ducted, with no language restrictions, minimising the
risk ofmissing information.The collection of data from
individual patients allowed us to use previously unre-
ported data, improve the assessment of study quality,
standardise outcome measures, undertake intention to
treat analysis, and use optimal analytical methods.
Subgroup, repeated measures, and multivariable ana-
lyses would not have been possible without the collec-
tion of individual data.
We were unable to retrieve individual data from at
least 35% of randomised women because researchers
did not agree to collaborate or could not be contacted.
The data that we did receive were sometimes incom-
plete and on occasions failed quality checks and so
were unusable. The review’s inferences are also lim-
ited by the inconsistent outcome measure used across
trials: studies involving endometrial destruction and
Mirena focused on comparing reduction in bleeding,
while hysterectomy trials focused onwomen’s satisfac-
tion, quality of life, and use of resources.
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Interpretation
We found that more women were dissatisfied after
endometrial destruction than after hysterectomy,
though this should be placed in context of longer oper-
ating time, total hospital stay, and recovery period for
hysterectomy. Rates of dissatisfaction were relatively
low for endometrial destruction, and it is an effective
alternative for women with abnormal uterine bleeding
who do not want amenorrhoea. While this review has
shown that hysterectomy is a relatively safe operation,
other studies with a more comprehensive follow-up of
large populations have shown higher levels of morbid-
ity after hysterectomy.6 In contrast, endometrial
destruction has low rates of complication.66 All these
factors need to be taken into consideration when con-
sidering any potential benefit of hysterectomy.
We found that secondgeneration techniques, such as
thermal balloon ablation (Thermachoice and
Cavaterm),46 67 68 the Novasure device,48 or microwave
(Microsulis),51 69were at least as effective as first genera-
tion techniques. Moreover, they are simpler and
quicker, require less skill on the part of the operator,
and can be attempted under local anaesthetic. Impor-
tantly, fewer operative complications have been
recorded. Thus they are clearly preferable to first gen-
eration techniques. The association of shorter uterine
cavity and lower dissatisfactionwith second generation
endometrial destruction could be because endoscopic
treatment is technically more difficult, though given
the borderline statistical significance it could also
have arisen by chance.
The comparisons involving Mirena were encoura-
ging, and given that it is a relatively cheap and mini-
mally invasive procedure, it could be considered first if
drug treatment for heavy bleeding fails.70 It could even
be an alternative to oral drug treatment as a first line
agent, but we did not examine this question in our
review. The current body of evidence comparing Mir-
ena withmore invasive techniques, however, is limited
and prohibits us making any strong conclusions about
the current findings of this treatment. Furthermore,
research on Mirena presents some specific difficulties
in interpretation because of the high proportion of
women discontinuing treatment. This can be seen in
the trial by Hurskainen et al,41 71 which comparedMir-
ena with hysterectomy. While the study was well
conducted and reported, the lack of further investiga-
tion into the analysis of the primary outcome measure
(EuroQol EQ-5D) made the interpretation that there
was no evidence of a difference questionable. Of the
119 women allocated to Mirena, 24 (20%) had under-
gone hysterectomy before themain analysis time point
at 12 months, with a further 13 (11%) no longer using
the Mirena. Unfortunately, missing data from indivi-
dual patients in this trialmeantwe couldnot investigate
further.
Implications for practice
Our review provides evidence that hysterectomy
reduces dissatisfaction compared with endometrial
destruction, and this information should be used as
part of consultation with women making a choice
about treatment options when initial drug treatment
fails to control heavymenstrual bleeding. Endometrial
destruction is satisfactory for a high proportion of
women, but, if complete cessation of bleeding is
sought, then hysterectomy could be offered. Although
the evidence is not strong, our findings concur with a
recent NICE recommendation that women should be
offered Mirena before more invasive procedures, par-
ticularly as this can be offered in primary care.11
Implications for research
Further investment in a randomised controlled trial
comparing hysterectomy with second generation
endometrial destruction would be of limited value,
given the similar efficacy of first and second generation
techniques.Questions remain about the long termclin-
ical effectiveness of all the treatments; evidence from
trials with longer term follow-up (four years ormore) is
limited to a handful of studies involving differing
comparisons.40 69 72 73 71 74 Mirena, in particular, versus
alternative forms of surgical treatment requires further
research. While the small studies included in this
review have indicated promising results for this treat-
ment, the substantial levels of non-compliance make
interpretation of outcomes difficult and casts some
doubt on the equivalent efficacy conclusions. The
cost effectiveness of all these treatments is currently
being examined in a concurrent study. Issues such as
discontinuation of Mirena will be an important factor.
Meta-analysis of data from individual patients is an
extremely powerful tool if used correctly75 and pro-
vides themost definitive possible synthesis of the avail-
able evidence. Such collaborative meta-analyses are
well established in cancer research and have greatly
influenced clinical practice, resulting in striking
improvements in, for example, survival after breast
cancer.28 Clinicians in specialty groups, such as gynae-
cology, need to be aware that contributing data from
individual patients is certainly as important as conduct-
ing the original research, if not more so. Consensus on
optimal outcome measures would also be helpful for
meta-analysis.
We thank all authors of identified trials for sending us their trial data and
the British and European Societies of Gynaecological Endoscopy for their
support and help with the review.
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